BrianHKushnerMD

Pediatric Hematology & Oncology • New York, NY

Professor of Pediatrics, Cornell University-Weill Medical College

Overview of Dr. Kushner

Dr. Brian Kushner is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals / Bellevue. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 41 years. He is one of 92 doctors at Memorial Sloan Kettering Cancer Center and one of 14 doctors at NYC Health + Hospitals / Bellevue who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.

Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021
Book by Phone+1(872) 221-5812
Is this information wrong?

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1983 - 1988
Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1978 - 1980
New York Presbyterian Hospital (Columbia Campus)Residency, Pediatrics, 1976 - 1978
Johns Hopkins University School of MedicineClass of 1976

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 1976 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2003-2014
America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
New York Magazine: Top Doctors Castle Connolly, 2002-2008, 2011-2012
Join now to see all

Clinical Trials

Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Start of enrollment: 1990 May 01
Completed
Phase 2
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Start of enrollment: 1992 Oct 01
Completed
Phase 2
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma Start of enrollment: 1994 Feb 01
Completed
Phase 2
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Start of enrollment: 2001 Mar 01
Completed
Phase 2
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma Start of enrollment: 2003 Jul 01
Completed
Phase 2
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma Start of enrollment: 2005 Jun 01
Completed
Phase 1
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma Start of enrollment: 2005 Sep 09
Completed
Phase 1
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma Start of enrollment: 2009 May 27
Active, not recruiting
Phase 1, Phase 2
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation Start of enrollment: 2010 Aug 01
Completed
Phase 2
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma Start of enrollment: 2010 Aug 12
Completed
Phase 2
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma Start of enrollment: 2010 Aug 01
Terminated
Phase 2
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow Start of enrollment: 2010 Aug 12
Completed
Phase 2
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma Start of enrollment: 2012 Dec 01
Active, not recruiting
Phase 1, Phase 2
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma Start of enrollment: 2014 Mar 01
Completed
Not Applicable
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma Start of enrollment: 2017 Jan 23
Active, not recruiting
Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma Start of enrollment: 2021 Aug 02
Recruiting
Phase 2
A Study of N9 Chemotherapy in Children With Neuroblastoma Start of enrollment: 2021 Jun 22
Recruiting
Early Phase 1
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma Start of enrollment: 2023 Sep 21
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial.
Irene Y Cheung, Audrey Mauguen, Shakeel Modak, Govind Ragupathi, Ellen M Basu, Stephen S Roberts, Brian H Kushner, Nai-Kong Cheung> ;JAMA Oncology. 2023 Feb 1
16 citations
Phase 1 study of intraventricularI-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.
Kim Kramer, Neeta Pandit-Taskar, Brian H Kushner, Pat Zanzonico, John L Humm, Ursula Tomlinson, Maria Donzelli, Suzanne L Wolden, Sophia Haque, Ira Dunkel, Mark M Souw...> ;Journal of Hematology & Oncology. 2022 Nov 12
Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma.
Kathryn R Tringale, Suzanne L Wolden, Dana L Casey, Brian H Kushner, Leo Luo, Neeta Pandit-Taskar, Mark Souweidane, Nai-Kong V Cheung, Shakeel Modak, Ellen M Basu, Kim...> ;Pediatric Blood & Cancer. 2023 Feb 1
2 citations
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National...
Julie R Park, Judith G Villablanca, Barbara Hero, Brian H Kushner, Keith Wheatley, Klaus H Beiske, Ruth L Ladenstein, Sylvain Baruchel, Margaret E Macy, Lucas Moreno, ...> ;Cancer. 2022 Nov 1
3 citations
Immunotherapy with anti-Gmonoclonal antibody in infants with high-risk neuroblastoma.
Brian H Kushner, Shakeel Modak, Kim Kramer, Ellen M Basu, Fiorella Iglesias-Cardenas, Stephen S Roberts, Nai-Kong V Cheung> ;International Journal of Cancer. 2023 Jan 15
9 citations
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuro...
Jaume Mora, Godfrey C Chan, Daniel A Morgenstern, Karsten Nysom, Melissa K Bear, Karen Tornøe, Brian H Kushner> ;Cancer Reports. 2023 Jan 1
3 citations
Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia.
Barbara Spitzer, Kayleigh D Rutherford, Gunes Gundem, Erin M McGovern, Nathan E Millard, Juan E Arango Ossa, Irene Y Cheung, Teng Gao, Max F Levine, Yanming Zhang, Jua...> ;Clinical Cancer Research. 2022 Apr 14
Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease.
Christina Fong, Brian H Kushner, Angela Di Giannatale, Gunes Gundem, Shanita Li, Stephen S Roberts, Ellen M Basu, Anita Price, Nai-Kong V Cheung, Shakeel Modak> ;Frontiers in Oncology. 2022 Jan 1
5 citations
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma.
Fiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, Kim Kramer, Brian H Kushner, Govind Ragupathi, Nai-Kong V Cheung, Shakeel Modak> ;Cancers. 2021 Dec 14
4 citations
Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma
Sanam Shahid, Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Elyssa M Rubin, Gunes Gundem, Elli Papaemmanuil, Stephen S. Roberts> ;Pediatric Blood & Cancer. 2021 Jul 31
5 citations
Differential Impact of ALK Mutations in Neuroblastoma
Tara O'Donohue, Nitya Gulati, Audrey Mauguen, Brian H. Kushner, M I Rodriguez-Sanchez, Nancy Bouvier, Stephen S. Roberts, Ellen M. Basu, Nai-Kong V. Cheung, Shakeel Modak> ;JCO Precision Oncology. 2021 Mar 19
2 citations
Re-thinking transplant for neuroblastoma.
Brian H. Kushner> ;Pediatric Blood & Cancer. 2021 Mar 4
4 citations
Mandibular metastases in neuroblastoma: Outcomes and dental sequelae.
Annu Singh, Shakeel Modak, Armand Karl Solano, Brian H. Kushner, Suzanne L. Wolden, Joseph M. Huryn, Cherry L. Estilo> ;Pediatric Blood & Cancer. 2021 Jan 28
45 citations
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression
Irene Y. Cheung, Nai-Kong V. Cheung, Shakeel Modak, Audrey Mauguen, Yi Feng, Ellen M. Basu, Stephen S. Roberts, Govind Ragupathi, Brian H. Kushner> ;Journal of Clinical Oncology. 2021 Jan 20
6 citations
Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience.
Ami Patel, Cheryl Fischer, Yi‐Chih Lin, Ellen M. Basu, Brian H. Kushner, Kevin C. De Braganca, Yasmin Khakoo> ;Pediatric Blood & Cancer. 2020 Aug 1
7 citations
Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma
L. Luo, Kim Kramer, Nai-Kong V. Cheung, Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts, Suzanne L. Wolden> ;Pediatric Blood & Cancer. 2020 Sep 1
5 citations
Assessment of pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric survivors of high-risk neuroblastoma.
Anne Stone, Danielle Novetsky Friedman, Brian H. Kushner, Suzanne L. Wolden, Shakeel Modak, Michael P. LaQuaglia, Jessica Costello, Xian Wu, Nai-Kong V. Cheung, Charle...> ;Pediatric Blood & Cancer. 2019 Aug 12
12 citations
Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.
Dana L. Casey, Brian H. Kushner, Nai-Kong V. Cheung, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts, Michael P. LaQuaglia, Suzanne L. Wolden> ;International Journal of Radiation Oncology, Biology, Physics. 2019 Feb 11
72 citations
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Tr...
Brian H. Kushner, Irene Y. Cheung, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung> ;JAMA Oncology. 2018 Dec 1
12 citations
Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities.
Stanislav Lazarev, Brian H. Kushner, Suzanne L. Wolden> ;International Journal of Radiation Oncology, Biology, Physics. 2018 Dec 1
6 citations
Enigmatic entities: opsoclonus myoclonus ataxia syndrome linked to neuroblastoma
Brian H. Kushner, Yasmin Khakoo> ;The Lancet. Child & Adolescent Health. 2018 Jan 1
55 citations
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.
Shakeel Modak, Jean-Benoît Le Luduec, Irene Y. Cheung, Debra A. Goldman, Irina Ostrovnaya, Ekaterina Doubrovina, Ellen M. Basu, Brian H. Kushner, Kim Kramer, Stephen S...> ;Oncoimmunology. 2018 May 10
17 citations
Treatment and outcome of adult-onset neuroblastoma
Maya Suzuki, Brian H. Kushner, Kim Kramer, Ellen M. Basu, Stephen S. Roberts, William J. Hammond, Michael P. LaQuaglia, Suzanne L. Wolden, Nai-Kong V. Cheung, Shakeel ...> ;International Journal of Cancer. 2018 Sep 1
19 citations
Dose-escalation is needed for gross disease in high-risk neuroblastoma.
Dana L. Casey, Brian H. Kushner, Nai-Kong V. Cheung, Shakeel Modak, Michael P. LaQuaglia, Suzanne L. Wolden> ;Pediatric Blood & Cancer. 2018 Feb 22
14 citations
Germline BRCA2 mutations detected in pediatric sequencing studies impact parents' evaluation and care.
Michael Walsh, Jennifer Kennedy, Megan Harlan, Alex Kentsis, Jacob Musinsky, Stephen S. Roberts, Andrew L. Kung, Mark E. Robson, Brian H. Kushner, Paul A. Meyers, Kenn...> ;Cold Spring Harbor Molecular Case Studies. 2017 Nov 1
Join now to see all

Lectures

High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Y-mAbs Announces Naxitamab UpdateOctober 25th, 2019

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York
NYC Health + Hospitals / BellevueNew York, New York